1. PI3K/Akt/mTOR
    Stem Cell/Wnt
  2. GSK-3
  3. LY2090314


Cat. No.: HY-16294 Purity: 99.75%
Handling Instructions

LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.

For research use only. We do not sell to patients.

LY2090314 Chemical Structure

LY2090314 Chemical Structure

CAS No. : 603288-22-8

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 135 In-stock
Estimated Time of Arrival: December 31
5 mg USD 120 In-stock
Estimated Time of Arrival: December 31
10 mg USD 190 In-stock
Estimated Time of Arrival: December 31
50 mg USD 550 In-stock
Estimated Time of Arrival: December 31
100 mg USD 950 In-stock
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 9 publication(s) in Google Scholar

Top Publications Citing Use of Products

    LY2090314 purchased from MCE. Usage Cited in: J Biol Chem. 2016 Dec 23;291(52):26875-26885.

    K562 cells expressing wild-type S-UNG2 are treated with the GSK-3 inhibitor LY2090314 (LY) for 90 min. Phosphorylation of UNG2 is detected with phospho-PLK1 motif antibody (top). UNG2 expression in input cell lysates is detected by Western blotting for the S tag (bottom).

    LY2090314 purchased from MCE. Usage Cited in: Stem Cell Reports. 2018 Dec 11;11(6):1539-1550.

    The CDX2 protein expression levels are measured by western blotting analysis in the treatment of SB216763, CHIR99021, LY2090314, BIO and BIO.DAPT.

    LY2090314 purchased from MCE. Usage Cited in: Stem Cell Reports. 2018 Dec 11;11(6):1539-1550.

    Immunostaining analysis of CDX2 (green) is performed in the human iPSC-derived intestinal progenitor cells in the treatment of LY2090314.

    View All GSK-3 Isoform Specific Products:

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review


    LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.

    IC50 & Target[1]


    0.9 nM (IC50)


    1.5 nM (IC50)

    In Vitro

    LY2090314 (20 nM) promotes a time-dependent stabilization of β-catenin total protein as well as an induction of Axin2. LY2090314 is highly selective towards GSK3 as demonstrated by its fold selectivity relative to a large panel of kinases. LY2090314 potently induces apoptotic cell death in a panel of melanoma cell lines irrespective of BRAF mutation status. Cell death induced by LY2090314 is dependent on β-catenin and GSK3β knockdown increases the sensitivity of cells to LY2090314. LY2090314 remains active in cell lines resistant to PLX4032 and has an independent mechanism of action[2].

    In Vivo

    LY2090314 exhibits high clearance (approximating hepatic blood flow) and a moderate volume of distribution (appr 1-2 L/kg) resulting in rapid elimination (half-life appr 0.4, 0.7, and 1.8-3.4 hours in rats, dogs, and humans, respectively). LY2090314 is rapidly cleared by extensive metabolism with negligible circulating metabolite exposures due to biliary excretion of metabolites into feces with no apparent intestinal reabsorption[1]. LY2090314 (25 mg/kg Q3D, i.v.) elevates Axin2 gene expression in vivo, demonstrates single agent activity in the A375 xenograft model of melanoma and enhances the efficacy of DTIC[2].

    Clinical Trial
    Molecular Weight




    CAS No.





    Room temperature in continental US; may vary elsewhere.

    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 31 mg/mL (60.48 mM)

    *"≥" means soluble, but saturation unknown.

    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.9511 mL 9.7555 mL 19.5111 mL
    5 mM 0.3902 mL 1.9511 mL 3.9022 mL
    10 mM 0.1951 mL 0.9756 mL 1.9511 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.5 mg/mL (4.88 mM); Clear solution

    *All of the co-solvents are provided by MCE.
    Animal Administration

    Five million A375 human melanoma cancer cells are injected S.C. in the flank of female 6 to 8 week old athymic nude mice in a 1:1 mixture with matrigel. Mice are monitored daily for palpable tumors. When tumors reach appr 100 mm2 mice are randomized into groups receiving either LY2090314 (25 mg/kg Q3D) or vehicle (20% Captisol/0.01N HCl) via i.v. administration. Tumor volume (measured by calipers) and animal body weight are recorded twice weekly. Tumor volumes are calculated using the formula: (a2 × b)/2 (a being the smaller and b being the larger dimension of the tumor). For combination studies with DTIC (60 mg/kg QD), LY2090314 is dosed at 2.5 mg/kg Q3D and tumor growth monitored.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.


    Purity: 99.75%

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2


    LY2090314LY 2090314LY-2090314GSK-3Glycogen synthase kinase-3Glycogen synthase kinase 3Inhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name



    Applicant name *


    Email address *

    Phone number *


    Organization name *

    Country or Region *


    Requested quantity *


    Bulk Inquiry

    Inquiry Information

    Product name:
    Cat. No.:
    MCE Japan Authorized Agent: